Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GSK2831781 in active ulcerative colitis
NL-OMON49796Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IMP731 in autoimmune colitis (3 arms), sponsored by GSK. Primary endpoints: Adverse events and serious adverse events up to Week 10, Potentially clinically important safety findings up to Week 10 and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
IMP731
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON49796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49796.